Evidence map›Paper›PMID 38812791›Full record

ArticleFrontiers in cellular neuroscience2024

A novel

Benjamin C Shaw, Jessica L Williams

Abstract read
In one paragraph

Article in Frontiers in cellular neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Benjamin C ShawDepartment of Neurosciences, Lerner Research Institute Cleveland Clinic, Cleveland, OH, United States.
Jessica L WilliamsDepartment of Neurosciences, Lerner Research Institute Cleveland Clinic, Cleveland, OH, United States.

Funding

Pathogenesis of Neurological Disability in Primary Diseases of MyelinR35NS097303 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI TRAPP, BRUCE D · 2017 to 2024
$6.9M
The role of the astrocyte immunoproteasome during chronic CNS autoimmunityR01NS119178 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI WILLIAMS, JESSICA L · 2021 to 2025
$2.0M
Translating Genetic Risk Factors to Therapies: From Big Data to Druggable TargetsK00NS120365 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI SHAW, BENJAMIN C. · 2022 to 2024
$253k
NINDS NIH HHS K00 NS120365NINDS NIH HHS R01 NS119178NINDS NIH HHS R35 NS097303
6 · The paper itself

Abstract

Introduction: Multiple sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous system (CNS). Current therapies primarily target the inflammatory component of the disease and are highly effective in early stages of MS while limited therapies have an effect in the more chronic progressive stages of MS where resident glia have a larger role. MS lesions tend to be inflammatory even after the initial peripheral immune cell invasion has subsided and this inflammation is known to cause alternative splicing events. Methods: We used qPCR of normal-appearing white matter and white matter lesions from postmortem MS tissue, Results: We found a novel, intron-retained isoform which has not been annotated, upregulated specifically in MS patient white matter lesions. We found that this novel isoform activates the nonsense-mediated decay pathway in primary human astrocytes, the most populous glial cell in the CNS, and is then degraded. Overexpression of this isoform in astrocytes leads to an increased number of processing bodies Discussion: The increase in alternative splicing of the

Indexed as

alternative splicingastrocytesmultiple sclerosisneuroinflammationnonsense-mediated decay

Identifiers

PMID38812791
PMCPMC11133558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.